Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$106.99 USD

106.99
4,492,494

-1.71 (-1.57%)

Updated Oct 21, 2024 02:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RODM

Bristol Myers (BMY) UC Candidate Fails in Phase II Study

by Zacks Equity Research

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $81.94, moving +1.59% from the previous trading session.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Neena Mishra headshot

Should You Invest in Travel & Tourism ETFs Now?

by Neena Mishra

Travel stocks could benefit from pent-up demand as we return to normal

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates when Tilray (TLRY) reports first-quarter fiscal 2022 results.

RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up

by Zacks Equity Research

Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.

Sweta Jaiswal, FRM headshot

ETFs to Play the Reopening Trade on Merck's Oral Antiviral Pill News

by Sweta Jaiswal, FRM

Let's take a look at ETFs that are well-poised to gain as the reopening of the U.S. economy may pick up further pace following Merck's announcement.

Maharathi Basu headshot

U.S. Aviation Stocks Gain After Update on Merk's COVID-19 Pill

by Maharathi Basu

Delta Air Lines (DAL) management's commentary that its ticket sales are improving bodes well.

Daniel Laboe headshot

Market Bears Take The Bulls By The Horns As Q4 Kicks Off

by Daniel Laboe

We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows

Sanghamitra Saha headshot

ETFs to Play Dow Jones' Best Start to October Since 2003

by Sanghamitra Saha

The Dow Jones has recorded its best start to October since 2003.

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Markets Wait for Major Economic and Earnings Data

by Zacks Equity Research

Markets Wait for Major Economic and Earnings Data.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19

Mark Vickery headshot

Topsy-Turvy Stock Markets to Start a New Week

by Mark Vickery

After 1% gains on Friday, which followed -2% losses for the full week, the Dow, S&P 500 and Nasdaq are all selling off again early Monday.

Stock Market News for Oct 4, 2021

by Zacks Equity Research

U.S. stocks rebound on Friday, the first trading day of the fourth quarter of 2021.

Sanghamitra Saha headshot

ETFs to Play as Merck Shares Surge on COVID Treatment News

by Sanghamitra Saha

Merck & Co shares gained 8.4% on Oct 1, 2021 on news of success in its COVID treatment.

Merck (MRK) Moves 8.4% Higher: Will This Strength Last?

by Zacks Equity Research

Merck (MRK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Core PCE Inflation Stays at Record-High in August

by Zacks Equity Research

Core PCE Inflation Stays at Record-High in August.

Mark Vickery headshot

Merck (MRK) Develops Pill to Lessen Covid Symptoms

by Mark Vickery

Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More

by Kinjel Shah

Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.

Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio

by Zacks Equity Research

Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

FDA Accepts Bristol Myers (BMY) sBLAs for Opdivo Combo for ESCC

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) sBLAs for Opdivo-based combinations as a potential treatment for esophageal squamous cell carcinoma.

Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal

by Zacks Equity Research

Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.